(Albany, USA) DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alzheimer’s Disease Market Forecast

 

Some of the key facts of the Alzheimer’s Disease Market Report: 

• The Alzheimer’s Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to estimates, there will be roughly 15,083,370 diagnosed cases of Alzheimer’s disease overall in the 7MM by 2022. This number is projected to rise by 2032 at a CAGR of 2.4% for the research period (2019–2032)
• In the 7MM confirmed instances of Alzheimer’s disease worldwide in 2022, which are projected to rise even more by 2032, the US accounted for roughly 41%
• According to the age-specific distribution of the disease, the age cohort of 75–84 years will account for the majority of instances of Alzheimer’s disease in the US in 2022 (45%), followed by 85 years and older (36%) in that country. The age group of people 65 years and older had the fewest cases
• According to the gender distribution of the disease, there will be more female cases than male cases in the 7MM in 2022, with 5,024,849 female cases and 10,058,521 male cases
• In 2022, there were roughly 4,942,376 diagnosed prevalent cases of Alzheimer’s disease in EU4 and the UK; this number is projected to rise during the study period (2019–2032).
• Key Alzheimer’s Disease Companies: BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, Novo Nordisk, Eisai, Neurim Pharmaceuticals/Syneos Health, Eli Lilly and Company, Whanin Pharma, Sanofi, Novartis, Chase Pharma, Forest Laboratories, Hoffmann-La Roche, Avid Radiopharma, H. Lundbeck A/S, Otsuka Pharma, Merck Sharp & Dohme LLC, TrueBinding, Inc., and others
• Key Alzheimer’s Disease Therapies: NE3107, Masitinib(AB1010), Donanemab(LY3002813), Simufilam(PTI-125), Semaglutide (NN6535), E2814, Piromelatine (Neu-P11), Remternetug (LY3372993), Aricept, SAR110894, ENA713, CPC-201, memantine ER, RO7126209, Gantenerumab, Florbetapir F18, Memantine, AVP-786, MK-1942, TB006, and others
• The Alzheimer’s Disease epidemiology based on gender analyzed that females are more affected with Alzheimer’s disease than males
• The Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alzheimer’s Disease pipeline products will significantly revolutionize the Alzheimer’s Disease market dynamics.

 

Alzheimer’s Disease Overview

Alzheimer’s disease is a neurological condition that affects the brain and progresses irreversibly. Its main symptoms include a deterioration in memory, thinking, and reasoning abilities. It accounts for between 60 to 80 percent of all dementia cases, making it the most prevalent dementia cause.

 

Get a Free sample for the Alzheimer’s Disease Market Report @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market

 

Alzheimer’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Alzheimer’s Disease Epidemiology Segmentation:

The Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Alzheimer’s Disease
• Prevalent Cases of Alzheimer’s Disease by severity
• Gender-specific Prevalence of Alzheimer’s Disease
• Diagnosed Cases of Episodic and Chronic Alzheimer’s Disease

 

Download the report to understand which factors are driving Alzheimer’s Disease epidemiology trends @ Alzheimer’s Disease Epidemiology Forecast

 

Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Alzheimer’s Disease Therapies and Key Companies

• NE3107: BioVie
• Masitinib(AB1010): AB Science
• Donanemab(LY3002813): Eli Lilly and Company
• Simufilam(PTI-125): Cassava Sciences
• Semaglutide (NN6535): Novo Nordisk
• E2814: Eisai
• Piromelatine (Neu-P11): Neurim Pharmaceuti cals/Syneos Health
• Remternetug (LY3372993): Eli Lilly and Company
• Aricept: Whanin Pharma
• SAR110894: Sanofi
• ENA713: Novartis
• CPC-201: Chase Pharma
• memantine ER: Forest Laboratories
• RO7126209: Hoffmann-La Roche
• Gantenerumab: Hoffmann-La Roche
• Florbetapir F18: Avid Radiopharma
• Memantine: H. Lundbeck A/S
• AVP-786: Otsuka Pharma
• MK-1942: Merck Sharp & Dohme LLC
• TB006: TrueBinding, Inc.

 

Discover more about therapies set to grab major Alzheimer’s Disease market share @ Alzheimer’s Disease Treatment Market

 

Alzheimer’s Disease Market Strengths

• Advances in structural and functional MRI techniques, along with biomarker assessments, have improved the understanding of anatomical and physiological changes in the brain, thereby increasing the evaluation of Alzheimer’s disease
• Approval of novel anti-amyloid biologics which are ‘disease-modifying’, with novel targeted mechanisms of action, have led to significant improvements from the traditional symptomatic treatment regime

 

Alzheimer’s Disease Market Opportunities

• Opportunity for companies to implement knowledge from recent advances in understanding to evaluate potential drugs with novel targets that are efficacious with a safe profile
• Progress in biomarker identification, drug discovery, and clinical trial endpoints increases confidence that better treatments will emerge from the AD drug development pipeline

 

Scope of the Alzheimer’s Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alzheimer’s Disease Companies: BioVie, AB Science, Eli Lilly and Company, Cassava Sciences, Novo Nordisk, Eisai, Neurim Pharmaceuti cals/Syneos Health, Eli Lilly and Company, Whanin Pharma, Sanofi, Novartis, Chase Pharma, Forest Laboratories, Hoffmann-La Roche, Avid Radiopharma, H. Lundbeck A/S, Otsuka Pharma, Merck Sharp & Dohme LLC, TrueBinding, Inc., and others
• Key Alzheimer’s Disease Therapies: NE3107, Masitinib(AB1010), Donanemab(LY3002813), Simufilam(PTI-125), Semaglutide (NN6535), E2814, Piromelatine (Neu-P11), Remternetug (LY3372993), Aricept, SAR110894, ENA713, CPC-201, memantine ER, RO7126209, Gantenerumab, Florbetapir F18, Memantine, AVP-786, MK-1942, TB006, and others
• Alzheimer’s Disease Therapeutic Assessment: Alzheimer’s Disease current marketed and Alzheimer’s Disease emerging therapies
• Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease market drivers and Alzheimer’s Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Alzheimer’s Disease Market Access and Reimbursement 

 

To know more about Alzheimer’s Disease companies working in the treatment market, visit @ Alzheimer’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Alzheimer’s Disease Market Report Introduction

2. Executive Summary for Alzheimer’s Disease

3. SWOT analysis of Alzheimer’s Disease

4. Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Alzheimer’s Disease Market Overview at a Glance

6. Alzheimer’s Disease Disease Background and Overview

7. Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Alzheimer’s Disease 

9. Alzheimer’s Disease Current Treatment and Medical Practices

10. Alzheimer’s Disease Unmet Needs

11. Alzheimer’s Disease Emerging Therapies

12. Alzheimer’s Disease Market Outlook

13. Country-Wise Alzheimer’s Disease Market Analysis (2019–2032)

14. Alzheimer’s Disease Market Access and Reimbursement of Therapies

15. Alzheimer’s Disease Market Drivers

16. Alzheimer’s Disease Market Barriers

17.  Alzheimer’s Disease Appendix

18. Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services